Patent intelligence · US
US 12097185
Compositions comprising ciprofloxacin and celecoxib
Compositions comprising ciprofloxacin and celecoxib
Patent details — US 12097185
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 24, 2024
- Expiration
- Sep 19, 2044
- Applicant
- NEUROSENSE THERAPEUTICS LTD.
- Claims
- 20
- CPC classes
- A61K, A61K31/415, A61K31/496, A61K9/2054
Quick answer
US 12097185 (Compositions comprising ciprofloxacin and celecoxib) is held by NEUROSENSE THERAPEUTICS LTD.. Status: granted. Granted Sep 24, 2024. Expires Sep 19, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- NEUROSENSE THERAPEUTICS LTD.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/415, A61K31/496, A61K9/2054
More from NEUROSENSE THERAPEUTICS LTD.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12097185?
US 12097185 (Compositions comprising ciprofloxacin and celecoxib) is held by NEUROSENSE THERAPEUTICS LTD.. Status: granted. Granted Sep 24, 2024. Expires Sep 19, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12097185?
NEUROSENSE THERAPEUTICS LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 2 pharmaceutical patents for this assignee.
When does US 12097185 expire?
Our index shows an expiration date of Sep 19, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.